Bristol-Myers Squibb Co. (BMY) Shares Bought by Carret Asset Management LLC
Carret Asset Management LLC raised its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,500 shares of the biopharmaceutical company’s stock after buying an additional 193 shares during the period. Carret Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $2,905,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of BMY. Williams Jones & Associates LLC boosted its stake in Bristol-Myers Squibb by 1.6% in the first quarter. Williams Jones & Associates LLC now owns 396,296 shares of the biopharmaceutical company’s stock worth $25,315,000 after buying an additional 6,125 shares in the last quarter. Sii Investments Inc. WI boosted its stake in shares of Bristol-Myers Squibb by 100.0% in the first quarter. Sii Investments Inc. WI now owns 33,090 shares of the biopharmaceutical company’s stock valued at $2,115,000 after buying an additional 16,542 shares during the period. Investment Centers of America Inc. boosted its stake in shares of Bristol-Myers Squibb by 30.3% in the first quarter. Investment Centers of America Inc. now owns 51,819 shares of the biopharmaceutical company’s stock valued at $3,310,000 after buying an additional 12,043 shares during the period. Wade G W & Inc. boosted its stake in shares of Bristol-Myers Squibb by 7.9% in the first quarter. Wade G W & Inc. now owns 22,081 shares of the biopharmaceutical company’s stock valued at $1,411,000 after buying an additional 1,616 shares during the period. Finally, RKL Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter valued at about $319,000. 72.88% of the stock is owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Co. (NYSE:BMY) opened at 49.55 on Wednesday. The stock has a market capitalization of $82.79 billion, a price-to-earnings ratio of 28.98 and a beta of 0.74. Bristol-Myers Squibb Co. has a 12-month low of $49.50 and a 12-month high of $77.12. The firm has a 50-day moving average of $55.86 and a 200 day moving average of $66.63.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.03. Bristol-Myers Squibb had a net margin of 16.63% and a return on equity of 24.92%. The company earned $4.90 billion during the quarter, compared to analysts’ expectations of $4.60 billion. During the same quarter last year, the company posted $0.53 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb Co. will post $2.63 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 1st. Stockholders of record on Friday, October 7th will be given a dividend of $0.38 per share. The ex-dividend date is Wednesday, October 5th. This represents a $1.52 annualized dividend and a dividend yield of 3.07%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 87.36%.
Several equities research analysts have recently issued reports on the company. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $75.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday. Barclays PLC reaffirmed an “equal weight” rating on shares of Bristol-Myers Squibb in a report on Wednesday. SunTrust Banks Inc. reaffirmed a “hold” rating and issued a $62.00 target price (down from $68.00) on shares of Bristol-Myers Squibb in a report on Monday. Leerink Swann reaffirmed a “buy” rating and issued a $69.00 target price on shares of Bristol-Myers Squibb in a report on Sunday. Finally, Citigroup Inc. reduced their target price on Bristol-Myers Squibb from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, September 20th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $69.31.
In other news, Director Lamberto Andreotti sold 23,200 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $59.17, for a total transaction of $1,372,744.00. Following the completion of the sale, the director now directly owns 364,999 shares of the company’s stock, valued at approximately $21,596,990.83. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.24% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.